Clinical trial
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally…
NCT00146276 · Association of Urologic Oncology (AUO), Other · Unknown status
Key facts
| NCT number | NCT00146276 |
|---|---|
| Title | Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer |
| Official title | Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study |
| Lead sponsor | Association of Urologic Oncology (AUO), Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Carcinoma, Transitional Cell |
| Intervention type | Drug |
| Interventions | gemcitabine |
| Enrollment | 178 |
| Start date | Jul 1, 2000 |
| First posted | Sep 7, 2005 |
| Last update posted | Sep 27, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: